Navigation Links
Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
Date:10/31/2011

BLUE BELL, Pa., Oct. 31, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon® vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines (see VGX-3100 – Cervical cancer). Inovio is currently enrolling patients with CIN 2/3 or CIN 3 cervical dysplasias in its Phase II clinical study being conducted in multiple centers around the US and sites in Canada, Korea, South Africa and Australia.

The article noted: "Fierce Vaccines spotlights 10 therapeutic vaccines now being tested in humans and generating buzz. Those for cancer get the most attention, in part because their anticipated gentleness stands in such stark contrast to the known toxicities of conventional chemotherapies….

"[Inovio's] VGX-3100 is a therapeutic DNA vaccine candidate, now in Phase II testing for the treatment of cervical dysplasia and cancer caused by human papillomavirus (HPV) types 16 and 18. These sexually transmitted strains are thought to cause up to 70% of cervical cancer cases. Inovio is conducting Phase II clinical trials of related vaccine candidates based on DNA associated with leukemia and hepatitis C virus, and Phase I studies for influenza and HIV. The company's vaccine candidates are similar to gene therapy, in that they are designed to insert into patients' cells a piece of DNA coding for an antigenic protein related to a particular disease. In theory, if enough DNA can get into cells even temporarily, those cells will prod
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... 2015 Par Pharmaceutical Companies, Inc. announced today ... August 7, 2015 at 9:00 a.m. EDT to review ... June 30, 2015.  Par is privately held and currently ... its filings with the Securities and Exchange Commission and ... by following the instructions at http://www.parpharm.com/financialinfo .  Par ...
(Date:8/3/2015)... , Aug. 3, 2015   ConvergeHEALTH ... pharmaceutical company Allergan plc is expanding ... and Intermountain Healthcare to include women,s ... ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world clinical ... "We look forward to expanding our ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4
... Calif. and SPRINGFIELD, Va. Oct. 29 Varian Medical Systems, ... Foundation has placed an order for five Varian TrueBeam™ systems ... CURE Foundation, which placed the order in September, plans to ... the U.S. East Coast during 2011.   ...
... Accuray Incorporated (Nasdaq: ARAY ), a global ... Creekside Cancer Care on their use of the CyberKnife ... in the world to install and begin treating patients with ... and clinicians at Creekside Cancer Care quickly reported that average ...
Cached Medicine Technology:CURE Foundation Selects Varian Medical Systems to Supply Radiotherapy Technology for Five New Cancer Centers 2CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 2CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 3CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 4
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and ... chin. Kybella is similar to deoxycholic acid, which occurs naturally in the body and ... options to treat this area of the body. These are invasive procedures and very ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... Decatur, Illinois (PRWEB) , ... August 03, 2015 , ... ... (IBAM NA) effective July 31. , The acquisition includes all of IBAM NA’s ... the opportunity to have both, a robust regionally located business, as well as a ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... announced today that Joe Williams has joined its growing California employee benefits division. ... differentiated service model to his clients. Mr. Williams will be joining the newly ...
(Date:8/3/2015)... ... August 03, 2015 , ... Cambia Health Solutions has promoted ... the company’s Medicare and Federal Employee Programs (FEP) lines of business. , ... for members. In this role, Scott is responsible for overseeing the growth, finance ...
Breaking Medicine News(10 mins):Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... Highmark Blue Cross Blue Shield,United Concordia Companies, ... healthy smiles and lifestyles for Pittsburghers. Beginning at ... 19, a free clinic will,offer health information and ... For far too long, oral health has ...
... drug offers new hope , , FRIDAY, July 18 (HealthDay News) ... the search for treatments against Alzheimer,s disease. , In one ... The Lancet , an older drug called dimebon significantly improved ... failed to prevent the progression of Alzheimer,s -- even though ...
... 18 minSURG Corporation,producers of the TruFUSE(R) ... of minSURG International, Incorporated. The,international division has ... the TruFUSE procedure and products., CEO, ... Germany,Greece, South Korea, Netherlands, Singapore, Taiwan, Turkey ...
... is showing the benefits of resistance training in keeping older ... a postdoctoral research fellow with UQ and Blue Care, said ... age of 65 responded to resistance training. , "What ... improve muscle strength, power and functional performance." Dr Henwood said. ...
... the earliest events occurring immediately upon infection with HIV-I ... the immune system earlier than was previously understood. According ... the window of opportunity for successful intervention may be ... after transmission, as researchers had previously believed. , Appearing ...
... 2008 -- The legal and ethical issues facing medical ... than some other areas of medicine. Certain activities, such ... federal and state governments. Other activities, such as minimum ... state to state. , A number of distinguished ...
Cached Medicine News:Health News:Highmark Blue Cross Blue Shield, United Concordia and Catholic Charities Join Forces to Offer Free Health, Dental Services This Saturday 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4Health News:minSURG(TM) Corporation Launches International Division 2Health News:The benefits of a little resistance for older adults 2Health News:HIV conquers immune system faster than previously realized 2Health News:HIV conquers immune system faster than previously realized 3Health News:Legal and ethical issues in medical physics 2Health News:Legal and ethical issues in medical physics 3Health News:Legal and ethical issues in medical physics 4Health News:Legal and ethical issues in medical physics 5Health News:Legal and ethical issues in medical physics 6Health News:Legal and ethical issues in medical physics 7
The Vitatron Excellence SS+ lead series are endocardial silicone leads providing ease of handling and optimal pacing characteristics....
... The Vitatron Impulse II lead series ... designed to extend the longevity of ... efficient pacing. The high impedance of ... the small electrode surface, combined with ...
CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
Medicine Products: